Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer.

Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ
Clin Cancer Res. 2004 10 (4): 1219-25

PMID: 14977818 · DOI:10.1158/1078-0432.ccr-1404-02

MeSH Terms (22)

Adult Aged Aged, 80 and over Antineoplastic Agents, Hormonal CD56 Antigen Dendritic Cells Drug Resistance, Neoplasm Flow Cytometry Hematopoietic Stem Cells Humans Leukocytes, Mononuclear Lymphocytes Male Membrane Proteins Middle Aged Monocytes Placebos Prostate-Specific Antigen Prostatic Neoplasms Random Allocation Recombinant Proteins Time Factors

Connections (1)

This publication is referenced by other Labnodes entities: